Compare Medpace Holdings Inc (MEDP) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Victoria's Secret & Co — how do they compare? Medpace Holdings Inc trades at $519.93 (market cap $15.08B), while Victoria's Secret & Co trades at $88.33 (market cap $6.95B). The key difference: Medpace Holdings Inc is far larger — about 2.2× Victoria's Secret & Co's market cap, and Victoria's Secret & Co is trading nearer its 52-week high, Medpace Holdings Inc nearer its low. Which is the better fit depends on your goals.
| MEDP | VSXY | |
|---|---|---|
Market Cap | $15.08B | $6.95B |
Sector | Technology | Consumer Cyclical |
52-Week High | $620.59 | $88.50 |
52-Week Low | $308.88 | $18.72 |
Enterprise Value | $14.55B | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Victoria's Secret (VSXY) trades at $87.49, up 7.42% today, with a bullish technical signal and strong momentum. Recent earnings beats in Q3 2025, Q4 2025, and Q1 2026 highlight improving fundamentals, while international growth and product innovation drive positive sentiment. The stock is near its consensus price target of $88.56, with net cash flow turning positive in 2026 projections.
Outlook remains favorable with analyst consensus at Buy (55.56% of coverage), though valuation multiples like P/E of 32.45 and net margin of 3.12% suggest premium pricing. Risks include competitive pressures and reliance on international expansion, but institutional support and earnings momentum support upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
